Gene therapy trial targets Tough-to-Treat blood cancer
NCT ID NCT07211048
Summary
This early study is testing a new treatment called LCAR02, a gene injection designed to target CD19 on cancer cells, in up to 18 adults with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see how well it works to control the cancer. Researchers will also track how long the treatment stays in the body and monitor patients' responses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.